Technical Analysis for URGN - UroGen Pharma Ltd.

Grade Last Price % Change Price Change
grade F 23.16 2.30% 0.52
URGN closed up 2.3 percent on Friday, August 7, 2020, on approximately normal volume.
Earnings due: Aug 10
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical URGN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Up 3 Days in a Row Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.30%
Inside Day Range Contraction 2.30%
Oversold Stochastic Weakness 2.30%
Stochastic Buy Signal Bullish 2.98%
Outside Day Range Expansion 2.98%
Oversold Stochastic Weakness 2.98%
Slingshot Bearish Bearish Swing Setup 4.32%
Spinning Top Other 4.32%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Medicine Biopharmaceutical Cancer Surgery Chemotherapy Antineoplastic Drugs Overactive Bladder Non Muscle Invasive Bladder Cancer Interstitial Cystitis

Is URGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 37.075
52 Week Low 13.1184
Average Volume 140,786
200-Day Moving Average 26.23
50-Day Moving Average 25.16
20-Day Moving Average 23.57
10-Day Moving Average 22.80
Average True Range 1.06
ADX 11.42
+DI 20.60
-DI 21.10
Chandelier Exit (Long, 3 ATRs ) 22.77
Chandelier Exit (Short, 3 ATRs ) 24.71
Upper Bollinger Band 25.57
Lower Bollinger Band 21.57
Percent B (%b) 0.4
BandWidth 16.97
MACD Line -0.72
MACD Signal Line -0.70
MACD Histogram -0.0177
Fundamentals Value
Market Cap 301.29 Million
Num Shares 13 Million
EPS -1.67
Price-to-Earnings (P/E) Ratio -13.87
Price-to-Sales 20.42
Price-to-Book 4.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.53
Resistance 3 (R3) 24.46 23.95 24.30
Resistance 2 (R2) 23.95 23.60 23.98 24.22
Resistance 1 (R1) 23.55 23.38 23.75 23.62 24.15
Pivot Point 23.04 23.04 23.14 23.07 23.04
Support 1 (S1) 22.64 22.69 22.84 22.71 22.17
Support 2 (S2) 22.13 22.47 22.16 22.10
Support 3 (S3) 21.73 22.13 22.02
Support 4 (S4) 21.80